SG3 Management’s Celldex Therapeutics CLDX Stock Holding History

SG3 Management’s Portfolio CLDX Stock Details CLDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	–	Sell	-18,000	Closed	-$485K	–	322
2022 Q2	$485K	Buy	+18,000	New	+$523K	0.06%	213
2021 Q4	–	Sell	-4,000	Closed	-$216K	–	1069
2021 Q3	$216K	Buy	+4,000	New	+$188K	0.01%	760

Other funds holding CLDX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

SG3 Management's CLDX Position: Q1 2022 in Review

SG3 Management sold out of Celldex Therapeutics (CLDX) in Q1 2022, closing a stake of 17,500 shares — an estimated $676K sold.

SG3 Management first reported a position in CLDX in Q3 2021 and held it in 2 quarters. The position peaked at $1.27M in Q3 2021. 168 funds tracked by Wall St. Rank hold CLDX as of Q1 2022.

SG3 Management reported no remaining Celldex Therapeutics position as of Q1 2022 after selling out during the quarter.
SG3 Management sold 17,500 Celldex Therapeutics shares in Q1 2022, an estimated $676K.
SG3 Management first reported a position in Celldex Therapeutics in Q3 2021 and held it in 2 quarters.
SG3 Management's Celldex Therapeutics position peaked at $1.27M in Q3 2021.
168 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q1 2022.

Based on SG3 Management's 13F filing for Q1 2022, filed 16 May 2022.